# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...
Stifel analyst Rick Wise downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and raises the price target from $23 to...
Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.
Lake Street analyst Frank Takkinen downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowers the price target f...